Importin 3D structures: Difference between revisions
Michal Harel (talk | contribs) New page: ==3D structures of importin== Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} {{#tree:id=OrganizedByTopic|openlevels=0| *IPO-α **1ial – mIPO NLS-bind... |
Michal Harel (talk | contribs) No edit summary |
||
| Line 37: | Line 37: | ||
**[[4b8j]] – rIPO <br /> | **[[4b8j]] – rIPO <br /> | ||
**[[6bvt]] – mIPO NLS-binding domain <br /> | **[[6bvt]] – mIPO NLS-binding domain <br /> | ||
**[[4u5v]], [[4u5u]], [[4u5s]], [[4u5o]], [[4u5n]], [[4u5l]], [[4u58]], [[4u54]] – mIPO NLS-binding domain + inhibitor<br /> | |||
*''IPO-α 1 complex with NLS peptide'' | *''IPO-α 1 complex with NLS peptide'' | ||
| Line 46: | Line 47: | ||
**[[5w4e]], [[5w4f]], [[5w4g]] – hIPO NLS-binding domain + polymerase peptide<br /> | **[[5w4e]], [[5w4f]], [[5w4g]] – hIPO NLS-binding domain + polymerase peptide<br /> | ||
**[[5h43]] – hIPO NLS-binding domain + histone acetyltransferase KAT8<br /> | **[[5h43]] – hIPO NLS-binding domain + histone acetyltransferase KAT8<br /> | ||
**[[4mz5]], [[4mz6]] – mIPO NLS-binding domain + dUTPase<br /> | **[[4mz5]], [[4mz6]] – mIPO NLS-binding domain 70-528 + dUTPase<br /> | ||
**[[4oih]] – mIPO NLS-binding domain + guanine nucleotide exchange factor SRM1<br /> | **[[4oih]] – mIPO NLS-binding domain + guanine nucleotide exchange factor SRM1<br /> | ||
**[[5svz]] – mIPO NLS-binding domain + TAT NLS motif<br /> | **[[5svz]] – mIPO NLS-binding domain + TAT NLS motif<br /> | ||
| Line 67: | Line 68: | ||
**[[5u5p]], [[5u5r]] – mIPO NLS-binding domain + MLH1 peptide <br /> | **[[5u5p]], [[5u5r]] – mIPO NLS-binding domain + MLH1 peptide <br /> | ||
**[[5gxw]] – mIPO NLS-binding domain + NUMA peptide <br /> | **[[5gxw]] – mIPO NLS-binding domain + NUMA peptide <br /> | ||
**[[6iw8]], [[6iwa]] – mIPO NLS-binding domain + GM130 peptide <br /> | |||
**[[6k06]] – mIPO NLS-binding domain (mutant) + GM130 peptide <br /> | |||
**[[6mjl]] – mIPO NLS-binding domain + CHREBP peptide <br /> | |||
**[[6p6a]] – mIPO NLS-binding domain + NIT-2 peptide <br /> | |||
**[[6p6e]] – mIPO NLS-binding domain + PAC3 peptide <br /> | |||
**[[7jk7]] – mIPO NLS-binding domain + LSD1 peptide <br /> | |||
**[[4b8o]] – rIPO NLS-binding domain + SV40<br /> | **[[4b8o]] – rIPO NLS-binding domain + SV40<br /> | ||
**[[4b8p]] – rIPO NLS-binding domain + A89<br /> | **[[4b8p]] – rIPO NLS-binding domain + A89<br /> | ||
| Line 108: | Line 115: | ||
**[[3zio]], [[3zip]], [[3ziq]], [[3zir]] – mIPO NLS-binding domain + minor site-specific NLS <br /> | **[[3zio]], [[3zip]], [[3ziq]], [[3zir]] – mIPO NLS-binding domain + minor site-specific NLS <br /> | ||
**[[3zin]] – mIPO NLS-binding domain + nucleolar RNA helicase<br /> | **[[3zin]] – mIPO NLS-binding domain + nucleolar RNA helicase<br /> | ||
**[[7jjm]] – mIPO + LSD1 peptide <br /> | |||
*''IPO-α 2 complex with protein'' | *''IPO-α 2 complex with protein'' | ||
| Line 177: | Line 185: | ||
**[[5h2v]] – yIPO + ubiquitin-like specific protease<br /> | **[[5h2v]] – yIPO + ubiquitin-like specific protease<br /> | ||
**[[4zj7]] – yIPO + CDC14<br /> | **[[4zj7]] – yIPO + CDC14<br /> | ||
*IPO-β 5 (Karyopherin β 5) | |||
**[[6aho]] – yIPO <br /> | |||
*IPO-3 | |||
**[[7jjl]] – hIPO + LSD1 peptide <br /> | |||
*IPO-4B | *IPO-4B | ||
| Line 182: | Line 198: | ||
**[[5xah]] – hIPO residues 668-1081 <br /> | **[[5xah]] – hIPO residues 668-1081 <br /> | ||
**[[5xbk]] – hIPO residues 668-1081 + histone H3 peptide <br /> | **[[5xbk]] – hIPO residues 668-1081 + histone H3 peptide <br /> | ||
*IPO-5 | |||
**[[6xte]], [[6xu2]] – hIPO + antipain peptide <br /> | |||
*IPO-7 | *IPO-7 | ||